Topical Intranasal Tranexamic Acid in Epistaxis

Evaluation of the ?effect of Topical Intranasal Tranexamic Acid for Stopping Nose Bleeding in Patients with Epistaxis in the ENT Emergency Department

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210403050815N1

Enrollment

240

Registered

2021-04-10

Start date

2021-04-21

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epistaxis. Epistaxis

Interventions

Intervention 1: Intervention group: In the intervention group, medicated cotton pledgets soaked into IV formulation of tranexamic acid (tranexip, 500mg/5ml, Caspian Tamin) plus phenylephrine nasal dro

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Aged 18 or over Presenting to the Ear, Nose, and Throat emergency department (ED) with spontaneous, atraumatic anterior epistaxis, unresolved with simple first aid

Exclusion criteria

Exclusion criteria: Hemodynamically unstable Known allergy to tranexamic acid Lacking capacity or unwilling to give consent Known nasopharyngeal, nasal cavity or paranasal malignancy Pregnancy Already undergone prehospital nasal packing Prisoners Epistaxis caused by trauma (excluding simple nose picking) Any Known bleeding disorders Any recent use of anticoagulation drugs

Design outcomes

Primary

Measure	Time frame
Need for use of anterior nasal packing. Timepoint: at any time during that ED attendance after initial management. Method of measurement: determined by clinical judgment.	—

Secondary

Measure	Time frame
Need for use of electrical cauterization. Timepoint: at any time during ED attendance after initial intervention. Method of measurement: determined by clinical judgment of physician.;Rebleeding within 24 hours after presenting to ED. Timepoint: within 24 hours after treatment. Method of measurement: self-statement of the patient with telephone call.;Rebleeding within 1-7 days after presenting to ED. Timepoint: 1-7 days after presenting to ED. Method of measurement: self-statement of the patient with telephone call.;ED stay more than 2 hours. Timepoint: from presenting to ED to leaving the hospital. Method of measurement: This outcome variable will be evaluated and reported as a qualitative variable. The patients who have been discharged from ED after 2 hours from the presentation will be considered as positive cases for this variable.	—

Measure

Time frame

Need for use of electrical cauterization. Timepoint: at any time during ED attendance after initial intervention. Method of measurement: determined by clinical judgment of physician.;Rebleeding within 24 hours after presenting to ED. Timepoint: within 24 hours after treatment. Method of measurement: self-statement of the patient with telephone call.;Rebleeding within 1-7 days after presenting to ED. Timepoint: 1-7 days after presenting to ED. Method of measurement: self-statement of the patient with telephone call.;ED stay more than 2 hours. Timepoint: from presenting to ED to leaving the hospital. Method of measurement: This outcome variable will be evaluated and reported as a qualitative variable. The patients who have been discharged from ED after 2 hours from the presentation will be considered as positive cases for this variable.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMilad Hosseinialhashemi

Shiraz University of Medical Sciences

miladhashemi88@gmail.com+98 71 3626 7225

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 17, 2026